<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03458208</url>
  </required_header>
  <id_info>
    <org_study_id>BIOMET-IR</org_study_id>
    <nct_id>NCT03458208</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Metformin 1000 mg Tablets IR Versus Glucophage® 1000 mg Tablets IR In Normal Healthy Subjects Under Fasting and Fed Conditions</brief_title>
  <official_title>This Study Are Four-way Crossover, Open-label, Single-dose, Bioequivalence Study of Metformin (LLC &quot;GEROPHARM&quot;, Russia) 1000 mg Tablets Immediate Release Versus Glucophage® (Merck Santé S.A.S, France) 1000 mg Tablets Immediate Release in Normal Healthy Subjects Under Fasting and Fed Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geropharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geropharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bioequivalence Study of 2 formulation of metformin (Metformin GEROPHARM vers. Glucophage®
      Merck )
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study to evaluate the bioequivalence of orally administered metformin preparations, immediate
      release tablets, 1 000 mg in normal healthy subjects under fasting and fed conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 14, 2017</start_date>
  <completion_date type="Actual">March 2, 2017</completion_date>
  <primary_completion_date type="Actual">March 2, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>four-way crossover</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 26 hours post-dose</time_frame>
    <description>Pharmacokinetics of metformin by Assessment of Observed Maximum Plasma Concentration (Cmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t)</measure>
    <time_frame>0 hours (pre-dose), as well as at 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, 24.0, and 26 hours post-dose</time_frame>
    <description>Pharmacokinetics of metformin by Assessment of Area Under the Curve From Time Zero Extrapolated to &quot;t&quot; (AUC(0-t))</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>First aIntervention Period:
Single administered dose of Metformin (1 000 mg tablet immidiate relise) in a fasting condition
Third Intervention Period:
Single administered dose of Metformin (1 000 mg tablet immidiate relise) in a fed condition</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Glucophage®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Second Intervention Period:
Single administered dose of Glucophage® ( 1 000 mg tablet immidiate relise) in a fasting condition
Fourth Intervention Period:
Single administered dose of Glucophage® ( 1 000 mg tablet immidiate relise) in a fed condition</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>First aIntervention Period:
Single administered dose of Metformin (1 000 mg tablet immidiate relise) in a fasting condition</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>fasting condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage®</intervention_name>
    <description>Second Intervention Period:
Single administered dose of Glucophage® (1 000 mg tablet immidiate relise) in a fasting condition</description>
    <arm_group_label>Glucophage®</arm_group_label>
    <other_name>fasting condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Third Intervention Period:
Single administered dose of Metformin (1 000 mg tablet immidiate relise) in a fed condition</description>
    <arm_group_label>Metformin</arm_group_label>
    <other_name>fed condition</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucophage®</intervention_name>
    <description>Fourth Intervention Period:
Single administered dose of Metformin (1 000 mg tablet immidiate relise) in a fed condition</description>
    <arm_group_label>Glucophage®</arm_group_label>
    <other_name>fed condition</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent form.

          -  Healthy male and female subjects aged 18 to 45 years.

          -  Verified diagnosis is &quot;healthy&quot; according to data Standard clinical, laboratory and
             Instrumental methods of examination.

          -  Have a body mass index between 18,5 and 27 kg/m2.

          -  Females must have a negative pregnancy test.

          -  Subjects must use, with their partner, methods of highly effective contraception
             throughout the study and 30 days after the end of study.

        Exclusion Criteria:

          -  History of serious allergic problems/events

          -  Medicinal intolerance.

          -  History of allergic reactions to memantine or investigator's product components

          -  Any acute and chronic diseases of the cardiovascular system, cardiovascular,
             bronchopulmonary, neuroendocrinal systems, as well as diseases of the gastrointestinal
             tract, liver, kidneys, blood.

          -  Acute infectious diseases in less than 4 weeks before the start of the study.

          -  Subjects who have taken medication 4 weeks preceding before the study.

          -  Subjects who have taken any drugs known effects on hemodynamics or to induce or
             inhibit hepatic drug metabolism within 30 days prior to administration of the study
             medication (examples of inducers: barbiturates, omeprazole, etc.).

          -  Donation of plasma (450 mL or more) within 2 month prior to administration of the
             study medication.

          -  History of significant alcohol or drugs abuse or any indication of the regular use of
             more than 10 units of alcohol per week (1 Unit = 200 mL of wine or 500 mL of beer or
             50 mL of alcohol 40%).

          -  Smokers.

          -  Participation in other clinical training is less than than for 3 months before the
             study.

          -  Lack of signed informed consent form.

          -  ECG or vital signs abnormalities (clinically significant).

          -  Positive testing for alcohol, drugs, pregnancy.

          -  Dehydration due to diarrhea, vomiting, or other causes within the last 24 hours before
             the start of the study.

          -  Any diet, for example, vegetarian, for 2 weeks before taking the study medications.

          -  Women with preserved reproductive potential who have unprotected sexual intercourse
             with an unsterilized male partner within 30 days prior to taking the study medication.

          -  Heart rate below 60 or above 80 beats per minute.

          -  Systolic blood pressure less than 110 mm Hg or more than 139 mm Hg.

          -  Diastolic blood pressure less than 70 mm Hg or more than 89 mm Hg.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sergey M Noscor, MD, Doctor of science</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yarosslavl Clinical Hospital #3</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yarosslavl Clinical Hospital #3</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 26, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 8, 2018</study_first_posted>
  <last_update_submitted>March 1, 2018</last_update_submitted>
  <last_update_submitted_qc>March 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AUC</keyword>
  <keyword>Cmax</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>metformin</keyword>
  <keyword>fed</keyword>
  <keyword>fasting</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

